WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO1998000135) TREATMENT OF SEPSIS-INDUCED ACUTE RENAL FAILURE AND RENAL VASOCONSTRICTION AND CATECHOLAMINE-INDUCED RENAL AND MESENTERIC VASOCONSTRICTION
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/1998/000135    International Application No.:    PCT/US1997/011389
Publication Date: 08.01.1998 International Filing Date: 01.07.1997
Chapter 2 Demand Filed:    13.01.1998    
IPC:
A61K 31/00 (2006.01), A61K 31/4174 (2006.01)
Applicants: UNIVERSITY OF PITTSBURGH [US/US]; Cathedral of Learning, Pittsburgh, PA 15260 (US)
Inventors: JACKSON, Edwin, K.; (US).
CARCILLO, Joseph, A.; (US)
Agent: SAMWAYS, Ian, K.; Reed Smith Shaw & McClay, P.O. Box 488, Pittsburgh, PA 15230 (US)
Priority Data:
08/675,115 03.07.1996 US
Title (EN) TREATMENT OF SEPSIS-INDUCED ACUTE RENAL FAILURE AND RENAL VASOCONSTRICTION AND CATECHOLAMINE-INDUCED RENAL AND MESENTERIC VASOCONSTRICTION
(FR) TRAITEMENT DE L'INSUFFISANCE RENALE AIGUE ET DE LA VASOCONSTRICTION RENALE D'ORIGINE INFECTIEUSE, ET DE LA VASOCONSTRICTION RENALE ET MESENTERIQUE PROVOQUEE PAR LES CATECHOLAMINES
Abstract: front page image
(EN)Methods are provided for treating sepsis/endotoxin-induced acute renal failure, and renal vasoconstriction and catecholamine-induced renal and mesenteric vasoconstriction by administering to a patient a therapeutically effective amount of a composition comprising at least one drug with Type IV phosphodiesterase inhibiting activity or any combination thereof and a pharmaceutically acceptable carrier.
(FR)L'invention concerne des méthodes qui permettent de traiter l'insuffisance rénale aiguë d'origine septique/endotoxinique, ainsi que la vasoconstriction rénale et mésentérique provoquée par les catécholamines. Ces méthodes consistent à administrer à un patient une dose thérapeutique efficace d'une composition qui contient au moins un médicament ayant une activité inhibitrice de la phosphodiestérase de type IV, ou une combinaison de celle-ci avec un excipient pharmaceutiquement acceptable.
Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW.
African Regional Intellectual Property Organization (GH, KE, LS, MW, SD, SZ, UG, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)